Publication:

Revumenib: the newly approved food drug administration drug for the treatment of relapsed acute leukemia with a KMT2A translocation

On November 15, 2024, the US food and drug administration (FDA) granted approval for Revumenib for the treatment of relapsed or refractory acute leukemia in adult patients and pediatric patients aged 12 months or older who exhibit a lysine methyltransferase 2A (KMT2A) translocation. This subset of acute leukemia is driven by the pathological interaction between menin proteins and the KMT2A gene, a critical epigenetic regulator. This interaction facilitates the rearrangement of KMT2A, which underpins leukemogenesis, contributing to the pathophysiology in approximately 10% of acute leukemia cases.